XNAS · Healthcare · Biotechnology
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | Q1 2026 | 1.19 | 1.30 | +9.24% | $631.0M | ✅ Beat | -0.20% | +4.99% | — |
| 2026-02-11 | Q4 2025 | 1.33 | 1.47 | +10.53% | $622.0M | ✅ Beat | -0.90% | +2.46% | +3.16% |
| 2025-11-05 |
| Q3 2025 |
| 1.07 |
| 1.17 |
| +9.35% |
| $609.0M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-08-06 | Q2 2025 | 1.05 | 1.14 | +8.57% | $579.0M | ✅ Beat | — | — | — |
| 2025-02-11 | Q4 2024 | 1.05 | 1.16 | +10.48% | $594.0M | ✅ Beat | +0.28% | +1.86% | +1.33% |
| 2024-05-09 | Q1 2024 | 0.99 | 0.98 | -1.01% | $568.0M | ❌ Miss | +0.43% | -0.32% | -2.07% |
| 2024-02-15 | Q4 2023 | 0.99 | 1.15 | +16.16% | $596.0M | ✅ Beat | -0.37% | +3.30% | +0.07% |
| 2023-11-08 | Q3 2023 | 0.77 | 0.79 | +2.60% | $536.0M | ✅ Beat | -0.76% | -2.17% | +3.44% |
Showing last 8 quarters.